MA40972B1 - Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 - Google Patents

Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3

Info

Publication number
MA40972B1
MA40972B1 MA40972A MA40972A MA40972B1 MA 40972 B1 MA40972 B1 MA 40972B1 MA 40972 A MA40972 A MA 40972A MA 40972 A MA40972 A MA 40972A MA 40972 B1 MA40972 B1 MA 40972B1
Authority
MA
Morocco
Prior art keywords
binding molecules
bispecific antigen
antigen binding
cells targeting
activating
Prior art date
Application number
MA40972A
Other languages
English (en)
Inventor
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Christian Klein
Marina Bacac
Tina Weinzierl
Peter Bruenker
Anne Freimoser-Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA40972B1 publication Critical patent/MA40972B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de manière générale de nouvelles molécules bispécifiques de liaison à l'antigène destinées à activer les lymphocytes t et à les rediriger vers des cellules cibles spécifiques. De plus, la présente invention concerne des polynucléotides codant pour ces molécules bispécifiques de liaison à l'antigène, ainsi que des vecteurs et des cellules hôtes comprenant ces polynucléotides. L'invention concerne par ailleurs des méthodes pour produire les molécules bispécifiques de liaison à l'antigène précitées, et des méthodes pour les utiliser dans le traitement de maladies.
MA40972A 2014-11-20 2015-11-17 Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 MA40972B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14194147 2014-11-20
PCT/EP2015/076739 WO2016079076A1 (fr) 2014-11-20 2015-11-17 Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3

Publications (1)

Publication Number Publication Date
MA40972B1 true MA40972B1 (fr) 2020-11-30

Family

ID=52100988

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40972A MA40972B1 (fr) 2014-11-20 2015-11-17 Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3

Country Status (33)

Country Link
US (3) US20160208019A1 (fr)
EP (1) EP3221356B1 (fr)
JP (2) JP7146395B2 (fr)
KR (1) KR102648966B1 (fr)
CN (1) CN107074955B (fr)
AR (1) AR102732A1 (fr)
AU (1) AU2015348595B2 (fr)
BR (1) BR112017007086A2 (fr)
CA (1) CA2960929A1 (fr)
CL (1) CL2017000954A1 (fr)
CO (1) CO2017003048A2 (fr)
CR (1) CR20170203A (fr)
DK (1) DK3221356T3 (fr)
EA (1) EA201791121A1 (fr)
ES (1) ES2829829T3 (fr)
HR (1) HRP20201747T1 (fr)
HU (1) HUE051715T2 (fr)
IL (1) IL251292A0 (fr)
LT (1) LT3221356T (fr)
MA (1) MA40972B1 (fr)
MX (1) MX2017006571A (fr)
MY (1) MY184889A (fr)
PE (1) PE20170585A1 (fr)
PH (1) PH12017500939A1 (fr)
PL (1) PL3221356T3 (fr)
PT (1) PT3221356T (fr)
RS (1) RS61010B1 (fr)
SG (1) SG11201702976TA (fr)
SI (1) SI3221356T1 (fr)
TW (2) TWI756164B (fr)
UA (1) UA122676C2 (fr)
WO (1) WO2016079076A1 (fr)
ZA (1) ZA201701843B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
WO2012116927A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Protéines monovalentes de liaison à l'antigène
WO2013026839A1 (fr) 2011-08-23 2013-02-28 Roche Glycart Ag Anticorps bispécifiques spécifiques pour les antigènes d'activation des lymphocytes t et un antigène tumoral et procédés d'utiliation correspondants
CN104704004B (zh) 2012-10-08 2019-12-31 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
WO2014131694A1 (fr) 2013-02-26 2014-09-04 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
JP6133444B2 (ja) 2013-02-26 2017-05-24 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
CA2922912A1 (fr) * 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Anticorps a chaine legere variable commune echangee a domaine multispecifique
EA038958B1 (ru) 2014-08-04 2021-11-15 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
SI3221355T1 (sl) 2014-11-20 2021-01-29 F. Hoffmann-La Roche Ag Kombinirano zdravljenje z bispecifičnimi molekulami CD3, ki aktivirajo celice T in vežejo antigene in folatni receptor 1 (FoIR1) ter antagonisti za vezavo osi PD-1
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AR106201A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
CN108290954B (zh) 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
PL3433280T3 (pl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
EP3519437B1 (fr) * 2016-09-30 2021-09-08 F. Hoffmann-La Roche AG Anticorps bispécifiques dirigés contre p95her2
ES2898025T3 (es) * 2016-11-02 2022-03-03 Jounce Therapeutics Inc Anticuerpos contra PD-1 y sus usos
WO2018108759A1 (fr) * 2016-12-13 2018-06-21 F. Hoffmann-La Roche Ag Procédé de détermination de la présence d'un antigène cible dans un échantillon de tumeur
MX2019006955A (es) * 2016-12-19 2019-08-01 Hoffmann La Roche Terapia de combinacion con agonistas de 4-1bb orientados (cd137).
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
EP3638697A4 (fr) 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. Anticorps anti-il1rap et conjugués anticorps-médicament
KR20200026995A (ko) 2017-07-14 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 향상된 이중 특이성 폴리펩티드 분자
MX2020004573A (es) * 2017-11-01 2020-09-25 Hoffmann La Roche Terapia de combinacion con agonistas de ox40 dirigidos.
EP3502140A1 (fr) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Thérapie de combinaison d'agonistes d'icos ciblés contre la tumeur avec des molécules bispécifiques à cellules t
US20200339685A1 (en) * 2017-12-27 2020-10-29 Teneobio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
CN111712261A (zh) 2018-02-08 2020-09-25 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
WO2019177854A1 (fr) * 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anticorps anti-récepteur 1 aux folates et leurs utilisations
US20200407434A1 (en) * 2018-03-13 2020-12-31 Vascular Biogenics Ltd. Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules
CA3105415A1 (fr) * 2018-07-09 2020-01-23 Multitude Inc. Anticorps specifiques du recepteur alpha du folate
WO2020028269A2 (fr) * 2018-07-30 2020-02-06 Invenra Inc. Molécules multispécifiques de liaison aux treg
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
CN116121302A (zh) * 2018-09-27 2023-05-16 公益财团法人实验动物中央研究所 免疫缺陷小鼠
WO2020127618A1 (fr) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
US11672858B2 (en) 2018-12-21 2023-06-13 Hoffmann-La Roche Inc. Bispecific antibody molecules binding to CD3 and TYRP-1
JPWO2020246563A1 (fr) * 2019-06-05 2020-12-10
CA3140192A1 (fr) 2019-06-19 2020-12-24 Johannes Auer Procede de generation d'une cellule exprimant un anticorps multivalent, multispecifique par integration ciblee de multiples cassettes d'expression dans une organisation definie
KR20220024637A (ko) 2019-06-19 2022-03-03 에프. 호프만-라 로슈 아게 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
WO2020260326A1 (fr) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Nouveaux anticorps anti-icos et molécules de liaison à un antigène ciblant les tumeurs les comprenant
US20220348648A1 (en) * 2019-07-11 2022-11-03 Memorial Sloan Kettering Cancer Center Dll3-targeting antibodies and uses thereof
CN111018969A (zh) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 采用轻链select联合层析色谱纯化双特异性抗体的方法
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
AU2021291005A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and FolR1
MX2022015204A (es) * 2020-06-19 2023-01-05 Hoffmann La Roche Anticuerpos que se unen a cd3.
WO2021255146A1 (fr) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Anticorps se liant à cd3 et cea
MX2022016069A (es) * 2020-06-19 2023-02-02 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19.
EP4225786A2 (fr) * 2020-10-07 2023-08-16 Amgen Inc. Sélection rationnelle de blocs de construction pour l'assemblage d'anticorps multispécifiques
TW202233684A (zh) * 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
WO2023079493A1 (fr) * 2021-11-03 2023-05-11 Affimed Gmbh Liants de cd16a bispécifiques
WO2023161457A1 (fr) 2022-02-27 2023-08-31 Evobright Gmbh Anticorps bispécifiques dirigés contre cd277 et un antigène tumoral

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010158A (es) 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
PL3321286T3 (pl) * 2011-08-23 2021-05-31 Roche Glycart Ag Dwuswoiste cząsteczki wiążące antygen aktywujące limfocyty T
RS60217B1 (sr) * 2012-08-31 2020-06-30 Immunogen Inc Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
WO2014087863A1 (fr) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 Anticorps anti-folr1
US9522196B2 (en) 2012-12-25 2016-12-20 Kagoshima University Antibody recognizing folate receptors α and β
WO2014131694A1 (fr) * 2013-02-26 2014-09-04 Roche Glycart Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
CA2903258C (fr) * 2013-03-15 2019-11-26 Amgen Inc. Anticorps heterodimeres bispecifiques
KR20150130349A (ko) * 2013-03-15 2015-11-23 메르크 파텐트 게엠베하 4가 이중특이적 항체
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US20160257748A1 (en) * 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody

Also Published As

Publication number Publication date
MY184889A (en) 2021-04-29
RS61010B1 (sr) 2020-11-30
KR20170081188A (ko) 2017-07-11
AU2015348595B2 (en) 2021-06-10
PL3221356T3 (pl) 2021-01-11
JP7146395B2 (ja) 2022-10-04
AU2015348595A1 (en) 2017-04-20
BR112017007086A2 (pt) 2018-01-16
HUE051715T2 (hu) 2021-03-29
JP2021058189A (ja) 2021-04-15
CN107074955A (zh) 2017-08-18
CA2960929A1 (fr) 2016-05-26
ES2829829T3 (es) 2021-06-02
HRP20201747T1 (hr) 2020-12-25
IL251292A0 (en) 2017-05-29
US20160208019A1 (en) 2016-07-21
PE20170585A1 (es) 2017-05-11
PH12017500939A1 (en) 2017-11-27
KR102648966B1 (ko) 2024-03-19
EA201791121A1 (ru) 2018-04-30
CR20170203A (es) 2017-06-29
ZA201701843B (en) 2018-05-30
UA122676C2 (uk) 2020-12-28
EP3221356B1 (fr) 2020-09-02
WO2016079076A1 (fr) 2016-05-26
CO2017003048A2 (es) 2017-07-11
CN107074955B (zh) 2021-06-22
CL2017000954A1 (es) 2017-12-29
TW201632556A (zh) 2016-09-16
SI3221356T1 (sl) 2021-01-29
MX2017006571A (es) 2017-09-29
AR102732A1 (es) 2017-03-22
SG11201702976TA (en) 2017-05-30
US20220220224A1 (en) 2022-07-14
DK3221356T3 (da) 2020-11-02
EP3221356A1 (fr) 2017-09-27
TWI756164B (zh) 2022-03-01
JP2017536121A (ja) 2017-12-07
PT3221356T (pt) 2020-10-29
US20190031784A1 (en) 2019-01-31
LT3221356T (lt) 2020-11-25

Similar Documents

Publication Publication Date Title
MA40972B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
MA35448B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
PH12019500545A1 (en) Cd3 binding antibodies
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX2018016404A (es) Anticuerpos de union a cd3.
MY193112A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
MA39250B1 (fr) Protéines hybrides de l'interleukine-2 et leurs utilisations
EP4249066A3 (fr) Anticorps contre tigit
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
BR112012022102A2 (pt) polipeptídeos de ligação a a-beta.
UA116614C2 (uk) Антитіло до фактора d і його застосування
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
PH12016501366A1 (en) Novel anti-baff antibodies
EA201591791A1 (ru) Антитела pac1 человека
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201992206A1 (ru) Моноклональное антитело к pd-l1